{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:13:30Z","timestamp":1790111610338,"version":"4.0.1"},"reference-count":59,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T00:00:00Z","timestamp":1524614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["mSphere"],"published-print":{"date-parts":[[2018,4,25]]},"abstract":"<jats:p>This article evaluates the scientific and commercial rationales for the synthesis of horsepox virus. I find that the claimed benefits of using horsepox virus as a smallpox vaccine rest on a weak scientific foundation and an even weaker business case that this project will lead to a licensed medical countermeasure.<\/jats:p>","DOI":"10.1128\/msphere.00040-18","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T10:11:45Z","timestamp":1520331105000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["A Critical Analysis of the Scientific and Commercial Rationales for the<i>De Novo<\/i>Synthesis of Horsepox Virus"],"prefix":"10.1128","volume":"3","author":[{"given":"Gregory D.","family":"Koblentz","sequence":"first","affiliation":[{"name":"Schar School of Policy and Government, George Mason University, Arlington, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Tonix Pharmaceuticals announces demonstrated vaccine activity in first-ever synthesized chimeric horsepox virus","author":"Tonix Pharmaceuticals","year":"2017","unstructured":"Tonix Pharmaceuticals. 2017. Tonix Pharmaceuticals announces demonstrated vaccine activity in first-ever synthesized chimeric horsepox virus. Tonix Pharmaceuticals, New York, NY. https:\/\/www.tonixpharma.com\/news-events\/press-releases\/detail\/1052\/tonix-pharmaceuticals-announces-demonstrated-vaccine."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0188453"},{"key":"e_1_3_3_4_2","article-title":"Important questions global health and science leaders should be asking in the wake of horsepox synthesis","author":"Inglesby T","year":"2017","unstructured":"Inglesby T. 7 July 2017. Important questions global health and science leaders should be asking in the wake of horsepox synthesis. The Bifurcated Needle. http:\/\/www.bifurcatedneedle.com\/new-blog\/2017\/7\/7\/important-questions-global-health-and-science-leaders-should-be-asking-in-the-wake-of-horsepox-synthesis.","journal-title":"The Bifurcated Needle"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/hs.2017.0061"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1089\/hs.2017.0081"},{"key":"e_1_3_3_7_2","volume-title":"Investor presentation","author":"Tonix Pharmaceuticals","year":"2017","unstructured":"Tonix Pharmaceuticals. 2017. Investor presentation. Tonix Pharmaceuticals, New York, NY. https:\/\/seekingalpha.com\/filings\/pdf\/11901090.pdf. Accessed 10 March 2017."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/v7041726"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01833-15"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30445-0"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05779-11"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00945-06"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1707600"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/v9060142"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004123"},{"key":"e_1_3_3_16_2","volume-title":"The smallpox vaccination program: public health in an age of terrorism","author":"Institute of Medicine","year":"2005","unstructured":"Institute of Medicine. 2005. The smallpox vaccination program: public health in an age of terrorism. National Academies Press, Washington, DC."},{"key":"e_1_3_3_17_2","first-page":"106","article-title":"Update: adverse events following civilian smallpox vaccination\u2014United States, 2003","volume":"53","author":"Centers for Disease Control and Prevention","year":"2004","unstructured":"Centers for Disease Control and Prevention. 2004. Update: adverse events following civilian smallpox vaccination\u2014United States, 2003. MMWR Morb Mortal Wkly Rep 53:106\u2013107. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5305a4.htm.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.24.3283"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70242-5"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.4.555"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S3687"},{"key":"e_1_3_3_22_2","first-page":"45","volume-title":"World Health Organization. WHO Advisory Committee on Variola Virus Research: Report of the Eighteenth Meeting","author":"Samy N","year":"2017","unstructured":"Samy N. 2017. Update on the non-replicating smallpox vaccine IMVANEX (IMVAMUNE), p 45. In World Health Organization. WHO Advisory Committee on Variola Virus Research: Report of the Eighteenth Meeting, 2\u20133 November 2016. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/entity\/csr\/resources\/publications\/smallpox\/18-ACVVR-Final.pdf?ua=1."},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054407"},{"key":"e_1_3_3_24_2","first-page":"21","article-title":"Global Advisory Committee on Vaccine Safety, 2\u20133 December 2015","volume":"91","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. 2016. Global Advisory Committee on Vaccine Safety, 2\u20133 December 2015. Wkly Epidemiol Rec 91:21\u201331. http:\/\/www.who.int\/wer\/2016\/wer9103.pdf?ua=1.","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_3_3_25_2","volume-title":"Smallpox vaccine supply and strength","author":"National Institutes of Health","year":"2014","unstructured":"National Institutes of Health. 11 December 2014. Smallpox vaccine supply and strength. National Institutes of Health, Bethesda, MD. https:\/\/www.niaid.nih.gov\/diseases-conditions\/smallpox-vaccine."},{"key":"e_1_3_3_26_2","volume-title":"Bavarian Nordic gets a lift with smallpox vaccine contract worth up to $539 million","author":"Sagonowsky E","year":"2017","unstructured":"Sagonowsky E. 2017. Bavarian Nordic gets a lift with smallpox vaccine contract worth up to $539 million. FiercePharma, Questex, Newton, MA. http:\/\/www.fiercepharma.com\/vaccines\/following-prostvac-setback-bavarian-nordic-picks-up-539m-smallpox-stockpiling-contract."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00199-14"},{"key":"e_1_3_3_28_2","volume-title":"LC16m8 attenuated smallpox vaccine","author":"World Health Organization","unstructured":"World Health Organization. LC16m8 attenuated smallpox vaccine. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/csr\/disease\/smallpox\/lance_gordon.pdf."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.07.111"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1089\/hs.2017.0047"},{"key":"e_1_3_3_31_2","volume-title":"Biodefense market analysis by product, region and segment forecasts, 2014 to 2025","author":"Grand View Research","year":"2016","unstructured":"Grand View Research. 2016. Biodefense market analysis by product, region and segment forecasts, 2014 to 2025. Grand View Research, San Francisco, CA. https:\/\/www.grandviewresearch.com\/industry-analysis\/biodefense-market."},{"key":"e_1_3_3_32_2","volume-title":"Smallpox vaccine stockpile, SAGE 5\u20137 November 2013","author":"Costa A","year":"2013","unstructured":"Costa A. 2013. Smallpox vaccine stockpile, SAGE 5\u20137 November 2013. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/immunization\/sage\/meetings\/2013\/november\/1_Costa_Smallpox_SAGE_2013.pdf."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1017\/dmp.2014.100"},{"key":"e_1_3_3_34_2","author":"Bavarian Nordic","year":"2002","unstructured":"Bavarian Nordic. 2002. Annual report. Bavarian Nordic, Kvistgard, Denmark. https:\/\/doc.morningstar.com\/Document\/9d65d317a7c184ed.msdoc\/original?clientid=globaldocuments&key=52dbc583e101239.","journal-title":"Annual report"},{"key":"e_1_3_3_35_2","volume-title":"Prepared for pox","author":"Rabitz C","year":"2003","unstructured":"Rabitz C. 2003. Prepared for pox. Deutsche Welle, Bonn, Germany. http:\/\/www.dw.com\/en\/prepared-for-pox\/a-790176."},{"key":"e_1_3_3_36_2","unstructured":"Leigh D Evans R. 2004. Papers detail Labour donor\u2019s vaccine deal. The Guardian London United Kingdom. https:\/\/www.theguardian.com\/uk\/2004\/jun\/29\/politics.freedomofinformation."},{"key":"e_1_3_3_37_2","volume-title":"Singapore-US strategic dialogue on biosecurity: report from the second dialogue session, held in Singapore on November 12\u201313, 2014","author":"UPMC Center for Health Security","year":"2015","unstructured":"UPMC Center for Health Security. 2015. Singapore-US strategic dialogue on biosecurity: report from the second dialogue session, held in Singapore on November 12\u201313, 2014. UPMC Center for Health Security, Baltimore, MD."},{"key":"e_1_3_3_38_2","unstructured":"Davis M. 15 June 2004. Bioterrorism drugs put on fast track. Australian Financial Review Sydney Australia. www.afr.com."},{"key":"e_1_3_3_39_2","author":"Global Biodefense","year":"2017","unstructured":"Global Biodefense. 2017. Bavarian Nordic highlights smallpox orders, vaccine development. Global Biodefense, Seattle, WA. https:\/\/globalbiodefense.com\/2017\/11\/10\/bavarian-nordic-highlights-smallpox-orders-vaccine-development-progress\/.","journal-title":"Bavarian Nordic highlights smallpox orders, vaccine development"},{"key":"e_1_3_3_40_2","author":"Global Biodefense","year":"2017","unstructured":"Global Biodefense. 2017. Canadian Government orders additional smallpox vaccine. Global Biodefense, Seattle, WA. https:\/\/globalbiodefense.com\/2016\/06\/15\/canadian-government-orders-additional-smallpox-vaccine\/.","journal-title":"Canadian Government orders additional smallpox vaccine"},{"key":"e_1_3_3_41_2","volume-title":"Avis relatif \u00e0 la r\u00e9vision du plan variole","author":"Haut Conseil de la Sant\u00e9 Publique","year":"2012","unstructured":"Haut Conseil de la Sant\u00e9 Publique. 2012. Avis relatif \u00e0 la r\u00e9vision du plan variole. Haut Conseil de la Sant\u00e9 Publique, Paris, France. https:\/\/www.hcsp.fr\/explore.cgi\/avisrapportsdomaine?clefr=318."},{"key":"e_1_3_3_42_2","doi-asserted-by":"crossref","DOI":"10.4159\/harvard.9780674063150","volume-title":"Long shot: vaccines for national defense","author":"Hoyt K.","year":"2012","unstructured":"Hoyt K. 2012. Long shot: vaccines for national defense. Harvard University Press, Cambridge, MA."},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1089\/bsp.2011.0011"},{"key":"e_1_3_3_44_2","volume-title":"Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) implementation plan","author":"Department of Health and Human Services","year":"2012","unstructured":"Department of Health and Human Services. 2012. Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) implementation plan. Department of Health and Human Services, Washington, DC. https:\/\/www.medicalcountermeasures.gov\/media\/13962\/2012-phemce-implementation-plan.pdf."},{"key":"e_1_3_3_45_2","volume-title":"2016 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) strategy and implementation plan","author":"US Department of Health and Human Services","year":"2016","unstructured":"US Department of Health and Human Services. 2016. 2016 Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) strategy and implementation plan. Department of Health and Human Services, Washington, DC. https:\/\/www.phe.gov\/Preparedness\/mcm\/phemce\/Documents\/2016-phemce-sip.pdf."},{"key":"e_1_3_3_46_2","volume-title":"HHS boosts biodefense preparedness with smallpox vaccine for special populations","author":"US Department of Health and Human Services","year":"2017","unstructured":"US Department of Health and Human Services. 2017. HHS boosts biodefense preparedness with smallpox vaccine for special populations. Department of Health and Human Services, Washington, DC. https:\/\/www.phe.gov\/Preparedness\/news\/Pages\/smallpox-specialpops-28Sept2017.aspx."},{"key":"e_1_3_3_47_2","volume-title":"21st Century Cures Act: MCM-related cures provisions","author":"Food and Drug Administration","year":"2018","unstructured":"Food and Drug Administration. 2018. 21st Century Cures Act: MCM-related cures provisions. Food and Drug Administration, Silver Spring, MD. https:\/\/www.fda.gov\/EmergencyPreparedness\/Counterterrorism\/MedicalCountermeasures\/MCMLegalRegulatoryandPolicyFramework\/ucm566498.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery."},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1089\/bsp.2007.0030"},{"key":"e_1_3_3_49_2","volume-title":"Sanofi Pasteur completes the acquisition of Acambis","author":"Sanofi Pasteur","year":"2008","unstructured":"Sanofi Pasteur. 2008. Sanofi Pasteur completes the acquisition of Acambis. Sanofi Pasteur, Rockville, MD. http:\/\/www.vaccineplace.com\/docs\/ACQUISITION_ACAMBIS.pdf."},{"key":"e_1_3_3_50_2","volume-title":"CDC commissions Acambis for $425 million to supply smallpox vaccine","author":"Genetic Engineering and Biotechnology News","year":"2008","unstructured":"Genetic Engineering and Biotechnology News. 2008. CDC commissions Acambis for $425 million to supply smallpox vaccine. Genetic Engineering and Biotechnology News, New Rochelle, NY. http:\/\/www.genengnews.com\/gen-news-highlights\/cdc-commissions-acambis-for-425m-to-supply-smallpox-vaccine\/34285401."},{"key":"e_1_3_3_51_2","volume-title":"Emergent acquires Sanofi smallpox vaccine in deal worth up to $125 million","author":"Washington Business Journal","year":"2017","unstructured":"Washington Business Journal. 2017. Emergent acquires Sanofi smallpox vaccine in deal worth up to $125 million. Washington Business Journal, Washington, DC. https:\/\/www.bizjournals.com\/washington\/news\/2017\/07\/14\/emergent-bioslutions-acquires-sanofi-smallpox.html."},{"key":"e_1_3_3_52_2","volume-title":"Emergent BioSolutions to acquire raxibacumab from GSK","author":"Reuters","year":"2017","unstructured":"Reuters. 2017. Emergent BioSolutions to acquire raxibacumab from GSK. Reuters, London, United Kingdom. https:\/\/www.reuters.com\/article\/brief-emergent-biosolutions-to-acquire-r\/brief-emergent-biosolutions-to-acquire-raxibacumab-from-gsk-idUSASB0B9QT."},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2014.00113"},{"key":"e_1_3_3_54_2","article-title":"The synthesis of horsepox virus and the failure of dual-use research oversight","author":"Koblentz GD","year":"2018","unstructured":"Koblentz GD. 20 January 2018. The synthesis of horsepox virus and the failure of dual-use research oversight. Pandora Report. https:\/\/pandorareport.org\/2018\/01\/20\/the-synthesis-of-horsepox-virus-and-the-failure-of-dual-use-research-oversight\/.","journal-title":"Pandora Report"},{"key":"e_1_3_3_55_2","volume-title":"Report of the eighteenth meeting, 2\u20133 November 2016","author":"World Health Organization Advisory Committee on Variola Virus Research","year":"2016","unstructured":"World Health Organization Advisory Committee on Variola Virus Research. 2016 Report of the eighteenth meeting, 2\u20133 November 2016. World Health Organization, Geneva, Switzerland. http:\/\/www.who.int\/csr\/resources\/publications\/smallpox\/18-ACVVR-Final.pdf."},{"key":"e_1_3_3_56_2","volume-title":"United States Government policy for institutional oversight of life sciences dual use research of concern","author":"US Department of Health and Human Services","year":"2013","unstructured":"US Department of Health and Human Services. 2013. United States Government policy for institutional oversight of life sciences dual use research of concern. US Department of Health and Human Services, Washington, DC. https:\/\/www.phe.gov\/s3\/dualuse\/Documents\/oversight-durc.pdf."},{"key":"e_1_3_3_57_2","volume-title":"Recommended policy guidance for departmental development of review mechanisms for potential pandemic pathogen care and oversight (P3CO)","author":"Office of Science Technology and Policy","year":"2017","unstructured":"Office of Science Technology and Policy. 2017. Recommended policy guidance for departmental development of review mechanisms for potential pandemic pathogen care and oversight (P3CO). Office of Science Technology and Policy, Washington, DC. https:\/\/www.phe.gov\/s3\/dualuse\/Documents\/P3CO-FinalGuidanceStatement.pdf."},{"key":"e_1_3_3_58_2","article-title":"Data check: U.S. government share of basic research funding falls below 50%","author":"Mervis J","year":"2017","unstructured":"Mervis J. 9 March 2017. Data check: U.S. government share of basic research funding falls below 50%. Science http:\/\/www.sciencemag.org\/news\/2017\/03\/data-check-us-government-share-basic-research-funding-falls-below-50.","journal-title":"Science"},{"key":"e_1_3_3_59_2","volume-title":"Glowing plants","author":"Kickstarter","year":"2013","unstructured":"Kickstarter. April 2013. Glowing plants. Kickstarter, Brooklyn, NY. https:\/\/www.kickstarter.com\/projects\/antonyevans\/glowing-plants-natural-lighting-with-no-electricit\/description."},{"key":"e_1_3_3_60_2","volume-title":"Recommendations for the evaluation and oversight of proposed gain-of-function research","author":"National Science Advisory Board on Biosecurity","year":"2016","unstructured":"National Science Advisory Board on Biosecurity. 2016. Recommendations for the evaluation and oversight of proposed gain-of-function research. National Science Advisory Board on Biosecurity, Washington, DC."}],"container-title":["mSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mSphere.00040-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/mSphere.00040-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T12:26:48Z","timestamp":1693571208000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/mSphere.00040-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,25]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4,25]]}},"alternative-id":["10.1128\/mSphere.00040-18"],"URL":"https:\/\/doi.org\/10.1128\/msphere.00040-18","relation":{},"ISSN":["2379-5042"],"issn-type":[{"value":"2379-5042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,25]]},"assertion":[{"value":"2018-03-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00040-18"}}